Literature DB >> 2775621

Effects of ketoconazole on the polymorphic 4-hydroxylations of S-mephenytoin and debrisoquine.

J O Atiba1, T F Blaschke, G R Wilkinson.   

Abstract

Studies were undertaken in 12 normal, male subjects to determine whether a metabolic interaction occurs between ketoconazole and mephenytoin. A single dose (400 mg) of ketoconazole produced a reduction in the 0-8 h urinary R/S ratio of mephenytoin following oral administration (100 mg) of racemic drug and after 28 daily doses the median value was further reduced to 42.9% of its baseline value. Within 7 days following discontinuation of ketoconazole the enantiomeric ratio had returned to its pre-study value. These findings are consistent with ketoconazole being a potent in vivo inhibitor of mephenytoin's 4-hydroxylation and confirm the ability of such an interaction to be predicted by in vitro studies with human liver microsomes. By contrast, ketoconazole had a much smaller effect on the 0-8 h urinary metabolic ratio of debrisoquine, indicating that ketoconazole has a selective inhibitory effect on different forms of cytochrome P-450.

Entities:  

Mesh:

Substances:

Year:  1989        PMID: 2775621      PMCID: PMC1379898          DOI: 10.1111/j.1365-2125.1989.tb05409.x

Source DB:  PubMed          Journal:  Br J Clin Pharmacol        ISSN: 0306-5251            Impact factor:   4.335


  20 in total

1.  Human liver microsomal cytochrome P-450 mephenytoin 4-hydroxylase, a prototype of genetic polymorphism in oxidative drug metabolism. Purification and characterization of two similar forms involved in the reaction.

Authors:  T Shimada; K S Misono; F P Guengerich
Journal:  J Biol Chem       Date:  1986-01-15       Impact factor: 5.157

2.  Competitive inhibition of sparteine oxidation in human liver by beta-adrenoceptor antagonists and other cardiovascular drugs.

Authors:  S V Otton; T Inaba; W Kalow
Journal:  Life Sci       Date:  1984-01-02       Impact factor: 5.037

3.  Purification and characterization of the human liver cytochromes P-450 involved in debrisoquine 4-hydroxylation and phenacetin O-deethylation, two prototypes for genetic polymorphism in oxidative drug metabolism.

Authors:  L M Distlerath; P E Reilly; M V Martin; G G Davis; G R Wilkinson; F P Guengerich
Journal:  J Biol Chem       Date:  1985-07-25       Impact factor: 5.157

4.  S-mephenytoin hydroxylation phenotypes in a Swedish population determined after coadministration with debrisoquin.

Authors:  E J Sanz; T Villén; C Alm; L Bertilsson
Journal:  Clin Pharmacol Ther       Date:  1989-05       Impact factor: 6.875

5.  Ketoconazole: a potent inhibitor of cytochrome P-450-dependent drug metabolism in rat liver.

Authors:  J J Sheets; J I Mason
Journal:  Drug Metab Dispos       Date:  1984 Sep-Oct       Impact factor: 3.922

6.  Pharmacogenetics of mephenytoin: a new drug hydroxylation polymorphism in man.

Authors:  A Küpfer; R Preisig
Journal:  Eur J Clin Pharmacol       Date:  1984       Impact factor: 2.953

7.  The effect of ketoconazole on hepatic oxidative drug metabolism in the rat in vivo and in vitro.

Authors:  C G Meredith; A L Maldonado; K V Speeg
Journal:  Drug Metab Dispos       Date:  1985 Mar-Apr       Impact factor: 3.922

8.  Debrisoquine hydroxylation capacity: problems of assessment in two populations.

Authors:  T Inaba; S V Otton; W Kalow
Journal:  Clin Pharmacol Ther       Date:  1981-02       Impact factor: 6.875

9.  Phenotypic differences in mephenytoin pharmacokinetics in normal subjects.

Authors:  P J Wedlund; W S Aslanian; E Jacqz; C B McAllister; R A Branch; G R Wilkinson
Journal:  J Pharmacol Exp Ther       Date:  1985-09       Impact factor: 4.030

10.  Mephenytoin hydroxylation deficiency in Caucasians: frequency of a new oxidative drug metabolism polymorphism.

Authors:  P J Wedlund; W S Aslanian; C B McAllister; G R Wilkinson; R A Branch
Journal:  Clin Pharmacol Ther       Date:  1984-12       Impact factor: 6.875

View more
  7 in total

1.  Frequency of impaired mephenytoin 4'-hydroxylation in an Indian population.

Authors:  B S Doshi; R D Kulkarni; B L Chauhan; G R Wilkinson
Journal:  Br J Clin Pharmacol       Date:  1990-11       Impact factor: 4.335

Review 2.  Effects of the antifungal agents on oxidative drug metabolism: clinical relevance.

Authors:  K Venkatakrishnan; L L von Moltke; D J Greenblatt
Journal:  Clin Pharmacokinet       Date:  2000-02       Impact factor: 6.447

Review 3.  Clinical pharmacokinetic considerations in the elderly. An update.

Authors:  M T Kinirons; P Crome
Journal:  Clin Pharmacokinet       Date:  1997-10       Impact factor: 6.447

4.  Induction of polymorphic 4'-hydroxylation of S-mephenytoin by rifampicin.

Authors:  H H Zhou; L B Anthony; A J Wood; G R Wilkinson
Journal:  Br J Clin Pharmacol       Date:  1990-09       Impact factor: 4.335

5.  Effects of three cytochrome P450 inhibitors, ketoconazole, fluconazole, and paroxetine, on the pharmacokinetics of lasofoxifene.

Authors:  D Ouellet; C Bramson; D Roman; A E Remmers; E Randinitis; A Milton; M Gardner
Journal:  Br J Clin Pharmacol       Date:  2006-07-06       Impact factor: 4.335

6.  Single- and multiple-dose pharmacokinetics of bosentan and its interaction with ketoconazole.

Authors:  Paul L M van Giersbergen; Atef Halabi; Jasper Dingemanse
Journal:  Br J Clin Pharmacol       Date:  2002-06       Impact factor: 4.335

Review 7.  Clinical significance of the cytochrome P450 2C19 genetic polymorphism.

Authors:  Zeruesenay Desta; Xiaojiong Zhao; Jae-Gook Shin; David A Flockhart
Journal:  Clin Pharmacokinet       Date:  2002       Impact factor: 6.447

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.